BioCatalystWatch
GRFSWorkspace / GRFS / OverviewCompany library
Grifols SA logo

Grifols SA

Grifols SA (GRFS)

Website

Featured programme · 15% subcutaneous alpha-1 antitrypsin

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

Trimodulin

PreINDP1P2P3FilingApproved
Xembify®

Approved

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Trimodulin

PreINDP1P2P3FilingApproved
Xembify®

Approved

PreINDP1P2P3FilingApproved

Other pipelines

Trimodulin

PreINDP1P2P3FilingApproved
AMBAR®

PreINDP1P2P3FilingApproved
Xembify®

PreINDP1P2P3FilingApproved
albumin

PreINDP1P2P3FilingApproved
Xembify®

PreINDP1P2P3FilingApproved

Partner / License out

Approved / commercial

PreINDP1P2P3FilingApproved

SARS-CoV-2

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved
Flebogamma®

Approved

PreINDP1P2P3FilingApproved

Rabies virus

Approved

PreINDP1P2P3FilingApproved

History / paused

Flebogamma®

PreINDP1P2P3FilingApproved

Financial position

Cash and cash equivalents

Source and basis

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Shares outstanding

Ownership and institutions

Market Reaction / Supply Context

Market Structure

GRFS SEC archive